CrushSCI.com
109.5Average days
102Median days
27Fastest days
309Longest days
1502025 publications

Paper Review Records

All Paper Review Records

21 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

138 days

From anti-drug antibody incidence to clinical relevance: interpreting highly sensitive immunogenicity assays in biosimilars

Authors
Anita Krishnan; Somesh BP; Gaurav Mehta; Shilpa Ramaswamy; Soumen Chakraborty; Shyamapada MandalShow moreShow less
Affiliations
1. Biocon BiologicsShow moreShow less
Source PDF DOI Publisher page
91 days

From analytical similarity to clinical confidence: how regulatory evolution ensures comparable immunogenicity in streamlined biosimilar development

Authors
Sandra Ribes; Marc Rosenbaum; Laura Hartmann; Lisa Allmannsberger; Johann PoetzlShow moreShow less
Affiliations
1. Hexal AG (a Sandoz company)Show moreShow less
Source PDF DOI Publisher page
83 days

A validated bioanalytical LC-MS/MS method for the simultaneous determination of molnupiravir, N-hydroxycytidine, and baricitinib in human plasma

Authors
Fatma H. Ghazy; Ramzia I. El-Bagary; Samar H. Fahim; Sally T. MahmoudShow moreShow less
Affiliations
1. Cairo University; 2. School of Pharmacy, New GizaShow moreShow less
Source PDF DOI Publisher page
176 days

Electrochemiluminescence immunoassay for quantifying ZMA001 in human serum: method development, validation, and clinical pharmacokinetic application

Authors
Abdul-Azeez A. Lanihun; Oluwatobi T. Arisa; Olivia Poczatek; Yi Zeng; Nam Hoon Kwon; Sunghoon Kim; Sandra Cooper; Jason M. Elinoff; William D. FiggShow moreShow less
Affiliations
1. Clinical Pharmacology Laboratory, Clinical Center, National Institutes of Health, Bethesda, MD, USA; 2. Department of Pharmaceutical Sciences, College of Pharmacy, Howard University, Washington, DC, USA; 3. Research Institute, Zymedi Co., Ltd., Incheon, South Korea; 4. Department of Integrative Biotechnology, Interdisciplinary Graduate Program, Yonsei University, Incheon, South Korea; 5. Critical Care Medicine and Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA; 6. Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, USA; 7. Clinical Pharmacology Program, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USAShow moreShow less
Source PDF DOI Publisher page
27 days

Highlights from the 17th Japan Bioanalysis Forum Symposium

Authors
Katsutomo Hata; Naohito Yamada; Hiroyuki Shimizu; Tomoko Arakawa; Hitoshi Uchiyama; Miyuki Ugajin; Takeshi Okuzono; Eiichi Shimada; Masanori Nagata; Masayo Hashimoto; Hisanori Hara; Takashi Miyayama; Tamiki Mori; Ken-Ichi YamamotoShow moreShow less
Affiliations
1. Shionogi & Co., Ltd; 2. Tanabe Pharma Corporation; 3. Pfizer R&D Japan G.K; 4. Towa Pharmaceutical Co., Ltd; 5. Takeda Pharmaceutical Co., Ltd; 6. Sekisui Medical Co., Ltd; 7. Ono Pharmaceutical Co., Ltd; 8. Astellas Pharma Inc; 9. Otsuka Pharmaceutical Co., Ltd; 10. B2S Life Sciences LLC; 11. Chugai Pharmaceutical Co., Ltd; 12. Mediford Corporation; 13. Shin Nippon Biomedical Laboratories, LtdShow moreShow less
Source PDF DOI Publisher page
65 days

Investigating the relationship between relative accuracy and linearity acceptance criteria in bioassay validation for clinical studies

Authors
Pietro Piu; Stefano Auddino; Gioele Bernardoni; Emanuele Montomoli; Alessandro ManentiShow moreShow less
Affiliations
1. VisMederi S.r.l; 2. University of SienaShow moreShow less
Source PDF DOI Publisher page

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.